engleski

Changes in TFF3 peptide expression in luminal B breast carcinoma after neoadjuvant chemotherapy

Trefoil factor family 3 [TFF3] peptide is a small secretory protein important for mucosal protection which influences cell migration, differentiation and apoptosis, as well as angiogenesis. It is present in glandular epithelium of healthy breast, but also in breast cancer. Some researchers consider it a normal breast protein, and others believe it is oncogenic. Recent research shows that it may have a role in pathogenesis of breast tumors and might be considered as a molecular marker in assessment of tumor differentiation and malignancy. According to our recent research, Luminal B type of breast cancer has the strongest TFF3 peptide expression ; however, there is no data about the influence of neoadjuvant chemotherapy on the expression of TFF3 peptide in breast cancer. Tumor samples from 21 patients with Luminal B breast cancer were used. Core biopsies were used as pre-chemotherapy samples and surgical excisions of the same tumor after neoadjuvant chemotherapy were used as postchemotherapy samples. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded samples in Dako Autostainer Link 48 Slide Stainer using mouse monoclonal anti-TFF3 primary antibody and DakoEnVision FLEX system. TFF3 peptide expression was quantified in individual samples using the Modified Quick Score method for immunohistochemistry protein expression analysis. Our results revealed a significant reduction in TFF3 expression after neoadjuvant chemotherapy. Further research should be conducted in order to explain the mechanisms underlying this phenomenon and confirm or deny its clinical significance, e.g. in monitoring chemotherapy response in patients with breast cancer.

Breast tumor ; Trefoil Factor-3 ; Immunohistochemistry ; Biomarkers ; Neoadjuvant therapy

nije evidentirano